• OPEN AN ACCOUNT
Indian Indices
Nifty
26,033.75 47.75
(0.18%)
Sensex
85,747.83 482.51
( 0.57%)
Bank Nifty
59,288.70 -59.55
( -0.10%)
Nifty IT
38,360.25 535.00
( 1.41%)
Global Indices
Nasdaq
47,874.44 -29.46
(-0.06%)
Dow Jones
6,878.17 7.45
(0.11%)
Hang Seng
50,935.81 1,071.13
(2.15%)
Nikkei 225
9,722.32 30.25
(0.31%)
Forex
USD-INR
90.13 0.27
(0.30%)
EUR-INR
105.04 0.70
(0.67%)
GBP-INR
119.76 1.10
(0.93%)
JPY-INR
0.58 0.00
(0.57%)

EQUITY - MARKET SCREENER

Murae Organisor Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
542724
INE060601031
1.0194564
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
3.86
55.21
EPS(TTM)
Face Value()
Div & Yield %
0.07
1
0
 

Zydus enters into licensing and commercialization agreement with RK Pharma Inc.
Nov 26,2025
Zydus Lifesciences has entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.

Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US.

The product, developed under the 505(b)(2) pathway, is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals.